These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6494594)

  • 1. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin.
    Cella G; Scattolo N; Luzzatto G; Girolami A
    Res Exp Med (Berl); 1984; 184(4):227-9. PubMed ID: 6494594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal and low molecular weight heparins: interaction with human platelets.
    Fabris F; Fussi F; Casonato A; Visentin L; Randi M; Smith MR; Girolami A
    Eur J Clin Invest; 1983 Apr; 13(2):135-9. PubMed ID: 6223824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of heparin and a semi-synthetic heparin analogue, A73025. II. Some effects on platelet function.
    Michalski R; Lane DA; Kakkar VV
    Br J Haematol; 1977 Oct; 37(2):247-56. PubMed ID: 603758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.
    Mastacchi R; Barbanti M; Bianchini P; Osima B
    Agents Actions; 1986 Mar; 17(5-6):512-4. PubMed ID: 3518359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously.
    Bergqvist D; Hedner U; Sjörin E; Holmer E
    Thromb Res; 1983 Nov; 32(4):381-91. PubMed ID: 6658720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
    Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Esslinger HU; Breddin HK; Harder S
    Br J Clin Pharmacol; 2001 Sep; 52(3):297-305. PubMed ID: 11560562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
    Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 12. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.
    Bratt G; Törnebohm E; Lockner D; Bergström K
    Thromb Haemost; 1985 Apr; 53(2):208-11. PubMed ID: 4024029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF; May JA; Heptinstall S
    Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of platelets with standard heparin and low molecular weight fractions.
    Dunn FW; Soria C; Thomaidis A; Soria J; Dupuy E; Bellucci S; Tobelem G
    Nouv Rev Fr Hematol (1978); 1984; 26(4):249-53. PubMed ID: 6089103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of heparin fractions: old vs. new methods.
    Walenga JM; Fareed J; Hoppensteadt D; Emanuele RM
    Crit Rev Clin Lab Sci; 1986; 22(4):361-89. PubMed ID: 2936571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and beta TG/PF4 release.
    Cofrancesco E; Colombi M; Gianese F; Cortellaro M
    Thromb Res; 1990 Feb; 57(3):405-14. PubMed ID: 2138364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of unfractionated and fractionated heparin on platelet function.
    Heinrich D; Görg T; Schulz M
    Haemostasis; 1988; 18 Suppl 3():48-54. PubMed ID: 2840374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.